GDNF Therapy for Parkinson's Disease

GDNF Therapy for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GDNF Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Neurotrophic Factor Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Parkinson's Disease</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>GDNF infusion to protect/repair dopaminergic [neurons](/entities/neurons)</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Clinical Trials (Phase I/II)</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Year</td>
</tr>
<tr>
<td class="label">First human trial</td>
<td>1995</td>
</tr>
<tr>
<td class="label">Phase I trial</td>
<td>2002</td>
</tr>
<tr>
<td class="label">Phase II trial</td>
<td>2008</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Historical Trials (2000s)</td>
</tr>
<tr>
<td class="label">Delivery</td>
<td>Continuous infusion</td>
</tr>
<tr>
<td class="label">Targeting</td>
<td>Putamen</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Surgical</td>
<td>External devices</td>
</tr>
</table>

Introduction

GDNF Therapy for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GDNF Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Neurotrophic Factor Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Parkinson's Disease</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>GDNF infusion to protect/repair dopaminergic [neurons](/entities/neurons)</td>
</tr>
<tr>
<td class="label">Status</td>
<td>Clinical Trials (Phase I/II)</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Year</td>
</tr>
<tr>
<td class="label">First human trial</td>
<td>1995</td>
</tr>
<tr>
<td class="label">Phase I trial</td>
<td>2002</td>
</tr>
<tr>
<td class="label">Phase II trial</td>
<td>2008</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>Historical Trials (2000s)</td>
</tr>
<tr>
<td class="label">Delivery</td>
<td>Continuous infusion</td>
</tr>
<tr>
<td class="label">Targeting</td>
<td>Putamen</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Surgical</td>
<td>External devices</td>
</tr>
</table>

Introduction

Glial Cell Line-Derived Neurotrophic Factor (GDNF) is a potent neurotrophic factor that promotes the survival and function of dopaminergic neurons. GDNF therapy represents a promising disease-modifying approach for Parkinson's disease (PD), aiming to protect remaining dopaminergic neurons and potentially restore function to those that are damaged.

Molecular Mechanism

GDNF exerts its effects through the following cascade:

• PI3K/Akt pathway (cell survival)
• MAPK/ERK pathway (neuronal differentiation)
• PLCγ pathway (calcium signaling)

• Dopaminergic neuron survival
• Axonal outgrowth and regeneration
• Restoration of dopamine release
• Protection against oxidative stress

Clinical Development

Historical Trials

Current Approaches

Modern delivery methods under investigation:

AB-1005 (REGENERATE-PD) Phase 2 Trial

AB-1005 is an AAV2-based gene therapy delivering the GDNF gene directly to the putamen[@hovde2024].

• Mechanism: Adeno-associated virus serotype 2 (AAV2) delivering GDNF gene for continuous protein expression
• Delivery: Stereotactic injection to bilateral putamen
• Phase: Phase 2 clinical trial (REGENERATE-PD)
• ClinicalTrials.gov: NCT04815625
• Status: First patient treated in 2024
• Reference: [Hovde et al., Brain 2024](https://pubmed.ncbi.nlm.nih.gov/38547652/)

Key Differences from Historical Trials

Clinical Applications

Patient Selection

GDNF therapy is being investigated for:

• Early-to-mid stage Parkinson's disease
• Patients with preserved dopaminergic neurons
• Those showing positive response to levodopa
• Patients without cognitive impairment

Efficacy Measures

• Unified Parkinson's Disease Rating Scale (UPDRS) scores
• DaTscan imaging (dopaminergic transporter binding)
• PET imaging (glucose metabolism)
• CSF biomarkers ([α-synuclein](/proteins/alpha-synuclein), [neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain)

Challenges and Limitations

Future Directions

Promising Approaches

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Dopaminergic Neurons](/cell-types/dopaminergic-neurons)
• [Levodopa](/therapeutics/levodopa)
• [Deep Brain Stimulation](/therapeutics/deep-brain-stimulation)
• [Gene Therapy](/therapeutics/gene-therapy)
• [Neurotrophic Factors](/gdnf-family-neurotrophic-factor-signaling-pathway-in-neurodegeneration)

Background

The study of Gdnf Therapy For Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

External Links

• [Michael J. Fox Foundation - GDNF Research](https://www.michaeljfox.org/research-funding)
• [Parkinson's Foundation - Treatment Advances](https://www.parkinson.org/)
• [ClinicalTrials.gov - GDNF Trials](https://clinicaltrials.gov/)

Nurr1 in Neurodegeneration

Parkinson's Disease

• Nurr1 is essential for dopaminergic neuron survival
• Reduced Nurr1 expression in PD patients
• Gene therapy approaches to restore Nurr1
• Small molecule Nurr1 agonists in development

Transcriptional Targets

• Tyrosine hydroxylase (TH)
• Dopamine transporter (DAT)
• Vesicular monoamine transporter 2 (VMAT2)
• Retinoic acid receptor beta (RARβ)

Therapeutic Implications

• Nurr1 agonists for PD treatment
• Gene therapy with AAV-Nurr1
• Epigenetic modulators to enhance Nurr1 expression
• Combination with other neuroprotective factors

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
• [Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: ST3GAL2/ST8SIA1
• [Complement C1q Mimetic Decoy Therapy](/hypothesis/h-1fe4ba9b) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: C1QA
• [Circadian Glymphatic Rescue Therapy (Melatonin-focused)](/hypothesis/h-de579caf) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: MTNR1A

• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;
• [Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) &#x1f504;
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;